Skip to main navigation
Skip to search
Skip to main content
the UWA Profiles and Research Repository Home
Login
Home
Profiles
Organisations
Research output
Grants
Datasets
Prizes / Awards
Engagement / Activities
Press/Media
Units
Equipment
Impacts
Search by expertise, name or affiliation
PCSK9 inhibitors - mechanisms of action
Michael M Page
,
Gerald F Watts
Research output
:
Contribution to journal
›
Article
›
peer-review
61
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'PCSK9 inhibitors - mechanisms of action'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Biochemistry, Genetics and Molecular Biology
PCSK9
100%
Low-Density Lipoprotein
66%
LDL Receptor
50%
Blood Plasma
33%
Hepatocyte
16%
Proprotein Convertase
16%
Monoclonal Antibody
16%
Familial Hypercholesterolemia
16%
Medicine and Dentistry
Low Density Lipoprotein Cholesterol
100%
LDL Receptor
75%
Hepatocyte
25%
Familial Hypercholesterolemia
25%
Serine Proteinase
25%
Monoclonal Antibody
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Low Density Lipoprotein Cholesterol
100%
Low Density Lipoprotein Receptor
75%
Serine Proteinase
25%
Familial Hypercholesterolemia
25%
Monoclonal Antibody
25%
Diseases
25%
Immunology and Microbiology
Low-Density Lipoprotein
100%
Blood Plasma
28%
Monoclonal Antibody
14%